Ehave Inc (EHVVF)
0.0011
-0.0019 (-63.33%)
OP · Last Trade: Apr 5th, 11:19 AM EDT
Detailed Quote
Previous Close | 0.0030 |
---|---|
Open | 0.0010 |
Bid | - |
Ask | - |
Day's Range | 0.0010 - 0.0025 |
52 Week Range | 0.0001 - 0.0075 |
Volume | 102,378 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 306,853 |
Chart
News & Press Releases

Ehave, Inc. (OTC: EHVVF) has completed the first of three planned phases of its studies with the University of Melbourne to determine the cause and possible cure for hallucinogen-persisting perception disorder (HPPD).
Via Benzinga · February 3, 2023

After a full review of healthcare provider Ehave Inc.'s (OTC Pink: EHVVF) IND application, the U.S.
Via Benzinga · December 16, 2022

The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs.
Via Benzinga · June 8, 2022

Ehave, Inc. (OTC Pink: EHVVF) is a leading healthcare services and technology company focused on progressing psychedelics to therapeutics by engineering novel compounds and new treatment protocols for treating brain health.
Via Benzinga · June 1, 2022

Mycotopia Therapies (OTCPK:TPIA) subsidiary of Ehave, Inc. (OTCPK:EHVVF), has signed a definitive agreement to complete a triangular merger with Ei.Ventures, to form PSLY.COM. The companies anticipate closing the transaction on or about July 30, 2022.
Via Benzinga · May 23, 2022
Roth Capital Reveals Top Psychedelic Picks in New Industry Report
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report from Roth Capital is no exception. On April 19, Roth Capital analyst Elemer Piros issued an industry note outlining the significant upside potential of […]
Via FinancialNewsMedia · April 21, 2022
Ehave Inc. (Stock Symbol: EHVVF) Announces MetaHealthU Will Enter The Market With A Focus On HPPD
Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its MetaHealthU mobile application platform will focus on determining the cause and finding a possible cure for hallucinogen-persisting perception disorder (HPPD). Ehave has pioneered HPPD research efforts by launching a series of studies through its partnership with the University of Melbourne to gather data and biomarkers to target the condition. HPPD, (HPPD) or “flashbacks” is the only recognized long-term complication of hallucinogen use. It can cause a person to keep reliving the visual element of an experience caused by hallucinogenic drugs. As psychedelics become more widely accepted, the data and biomarkers from Ehave’s MetaHealthU will enhance research into HPPD, which will assist medical and mental health professionals to diagnose if an individual is genetically predisposed to suffer from the condition.
Via AB Newswire · April 20, 2022

Ehave, Inc. (OTC Pink: EHVVF), a healthcare company developing digital solutions in the medical cannabis and mental health sectors, reported that its wholly-owned subsidiary,...
Via Benzinga · February 15, 2022

The Week In Psychedelics
Via Benzinga · October 18, 2021

Greenlight Distribution Hires Erik Elder As New Director Of Sales
Greenlight Distribution, a leading seller of product...
Via Benzinga · September 25, 2021

Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors.
S...
Via Benzinga · October 13, 2021